VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully [Yahoo! Finance]